Optimizing Health of Children and Adolescents with Perinatal HIV Exposure (U19 Clinical Trial Optional)
ID: 353073Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353073

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-25-004.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Optimizing Health of Children and Adolescents with Perinatal HIV Exposure (U19 Clinical Trial Optional)." This initiative invites applications for cooperative agreements aimed at generating information and testing interventions related to the health outcomes of individuals exposed to HIV and/or antiretroviral therapy (ART) in utero but who are uninfected (IHEUs), focusing on long-term health effects associated with these exposures. The funding, part of a multi-program project grant, anticipates awarding 1-2 grants totaling approximately $9.48 million for FY 2025, with applications due by July 30, 2024. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-HD-25-004.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has announced a funding opportunity titled "Optimizing Health of Children and Adolescents with Perinatal HIV Exposure – U19 Clinical Trial Optional." This initiative invites applications for cooperative agreements aimed at generating information and testing interventions related to the health outcomes of individuals exposed to HIV and/or antiretroviral therapy (ART) in utero but who are uninfected (IHEUs). The goal is to address long-term health effects associated with these exposures, emphasizing innovative research approaches. The funding is part of a multi-program project grant that seeks to support synergistic research projects focused on adverse health effects related to ART exposure among IHEUs. Key areas of interest include immune system development, maternal co-infections, and mental health outcomes. The Notice of Funding Opportunity (NOFO) anticipates funding 1-2 awards totaling approximately $9.48 million for FY 2025. The submission deadline for applications is July 31, 2024, with an open date for applications beginning June 30, 2024. Detailed instructions for application submission and eligibility requirements are provided, emphasizing the importance of compliance with NIH guidelines and data management practices.
    Similar Opportunities
    Pediatric HIV/AIDS Cohort Study (PHACS) (U19 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Pediatric HIV/AIDS Cohort Study (PHACS), aimed at investigating the developmental and clinical trajectories of individuals living with HIV, particularly those with perinatally acquired HIV, focusing on youth into reproductive age. This initiative seeks to enhance understanding of HIV's long-term effects and improve health outcomes among affected populations, requiring applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP) as part of their proposals. The program will support a Scientific Administrative Core and a Data Management and Analysis Core, along with up to three research projects, with a total funding amount of up to $11 million over five years for 1-2 awards. Interested applicants should note that the application period opens on November 11, 2024, with a submission deadline of December 12, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    Mechanisms of Inducing HIV Immunity in Early Life (MIEL) (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Mechanisms of Inducing HIV Immunity in Early Life" (MIEL) under grant number RFA-AI-24-029. This initiative aims to support basic and applied research focused on understanding how immunity to HIV can be developed and maintained in children from birth to under 12 years old, particularly through the study of prophylactic vaccinations and broadly neutralizing antibodies (bNAbs). The NIH plans to commit $3 million for FY 2025 to fund 3-4 awards, with individual budgets not exceeding $750,000 per year. Applications are due by October 10, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Novel Preclinical Models of NeuroHIV in the cART Era (R61/R33 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Novel Preclinical Models of NeuroHIV in the cART Era" (Funding Opportunity Number: RFA-NS-24-035) aimed at developing innovative small animal models and human cellular systems that accurately reflect the interactions between the central nervous system (CNS) and the immune system in individuals living with HIV. This initiative seeks applications that propose the development and early-stage validation of next-generation humanized models to address cognitive and neurological impairments associated with chronic HIV infection, particularly in the context of antiretroviral therapy (ART). The total funding available for this initiative is approximately $6 million, with applications due by December 2, 2024. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Opportunities for HIV Cure Strategies at the Time of ART Initiation (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity aimed at exploring innovative HIV cure strategies at the initiation of combination antiretroviral therapy (cART). This initiative seeks to identify and develop interventions that can be applied at the start of cART or following treatment interruptions, with the ultimate goal of achieving sustained treatment-free remission. The funding, available for up to two years with a maximum budget of $275,000, is open to a diverse range of eligible applicants, including higher education institutions, non-profits, and for-profit entities. Interested parties can find more information and application guidelines at the NIH grants website, with a submission deadline set for September 7, 2026.
    Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting grant applications for the initiative titled "Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)." This funding opportunity aims to investigate the neuroimmune and neuronal-glial mechanisms associated with HIV-associated neurological disorders (HAND) using advanced ex vivo culturing platforms derived from human induced pluripotent stem cells (hiPSC) in the context of addictive substances. The research is critical for understanding the genetic, epigenetic, and neuroimmune interactions that contribute to HAND, particularly in the presence of substances like opioids and cocaine. The NIH has committed a total of $2 million annually for Fiscal Years 2024-2026, with applications due by 5 PM local time on August 13, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting proposals for the R21 Exploratory/Developmental Research Grant under the funding opportunity titled "Innovations to Optimize HIV Prevention and Care Continuum Outcomes." This initiative aims to support innovative research that enhances HIV prevention and care strategies by exploring behavioral and social science approaches, new intervention methods, and implementation science, particularly addressing gaps in engagement, adherence, and retention in healthcare services. The grant, with a funding ceiling of $275,000 over two years, emphasizes collaboration with community organizations and the inclusion of diverse populations, aligning with national and global health objectives. Interested applicants can submit their proposals until January 9, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders" through the R01 Research Project Grant. This initiative aims to support innovative and high-risk studies that explore the molecular mechanisms linking HIV and substance use disorders (SUDs), with a focus on advancing understanding of HIV dynamics within the Central Nervous System (CNS). The total estimated program funding is $2 million for fiscal year 2026, with the potential to support up to three awards, and applications must include clear milestones and human or primate studies. Interested applicants should note that the deadline for submitting letters of intent and applications is July 14, 2025, and no clinical trials are permitted under this grant. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS)," aimed at supporting multidisciplinary research teams investigating HIV pathogenesis and its associated comorbidities. The initiative seeks to foster collaboration among experts in HIV science, pathobiology, metabolism, and related fields to explore critical health issues such as gastrointestinal health, liver diseases, kidney function, and obesity in the context of HIV. With a total funding allocation of $2 million for 2-3 anticipated awards, applicants can request up to $500,000 per year for a maximum of five years, with proposals due by November 21, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details.
    Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34 Clinical Trial Optional)." This initiative aims to support formative research and pilot-testing of interventions designed to enhance HIV prevention and treatment outcomes, particularly focusing on innovative strategies that address mental health, social determinants, and structural factors affecting HIV care. The funding opportunity is crucial for developing effective HIV testing and treatment linkage strategies, ultimately contributing to national goals in HIV management and reducing health disparities among affected populations. Eligible applicants can receive direct costs up to $225,000 per year for a project duration not exceeding three years, with applications due by January 9, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-060.html.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.